Journal
CLINICAL INFECTIOUS DISEASES
Volume 52, Issue -, Pages S538-S541Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir169
Keywords
-
Categories
Funding
- Cempra Pharmaceuticals
Ask authors/readers for more resources
Presented is a case of chronic methicillin-resistant Staphylococcus aureus osteomyelitis, which was unsuccessfully treated with multiple courses of debridement and potent antibiotic therapies. Amputation of the patient's lower limb was believed to be the only option remaining. A compassionate access program, with approval from the US Food and Drug Administration and the institutional review board, enabled the patient to undergo a course of treatment with oral fusidic acid (CEM-102). The patient tolerated the drug well, with no significant toxicities noted to date. His infection improved rapidly, his flap healed, he has returned to work part-time, and he continues to take daily suppressive doses of oral CEM-102.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available